CN116490171A - 用于治疗帕金森病的阿片哌酮和左旋多巴 - Google Patents

用于治疗帕金森病的阿片哌酮和左旋多巴 Download PDF

Info

Publication number
CN116490171A
CN116490171A CN202180077619.0A CN202180077619A CN116490171A CN 116490171 A CN116490171 A CN 116490171A CN 202180077619 A CN202180077619 A CN 202180077619A CN 116490171 A CN116490171 A CN 116490171A
Authority
CN
China
Prior art keywords
levodopa
opiperidone
combination
pharmaceutically acceptable
acceptable derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180077619.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·M·维埃拉阿劳乔索莱斯达希尔瓦
J·F·达科斯塔德品霍洛查
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bial Portela and Cia SA
Original Assignee
Bial Portela and Cia SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela and Cia SA filed Critical Bial Portela and Cia SA
Publication of CN116490171A publication Critical patent/CN116490171A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180077619.0A 2020-10-16 2021-10-14 用于治疗帕金森病的阿片哌酮和左旋多巴 Pending CN116490171A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2016425.7A GB202016425D0 (en) 2020-10-16 2020-10-16 Treatment regimens for parkinson's disease
GB2016425.7 2020-10-16
PCT/PT2021/050036 WO2022081033A1 (en) 2020-10-16 2021-10-14 Opicapone and levodopa for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
CN116490171A true CN116490171A (zh) 2023-07-25

Family

ID=73598546

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180077619.0A Pending CN116490171A (zh) 2020-10-16 2021-10-14 用于治疗帕金森病的阿片哌酮和左旋多巴

Country Status (8)

Country Link
US (1) US20230398105A1 (https=)
EP (1) EP4228618A1 (https=)
JP (1) JP2023546140A (https=)
KR (1) KR20230088753A (https=)
CN (1) CN116490171A (https=)
AU (1) AU2021360114A1 (https=)
GB (1) GB202016425D0 (https=)
WO (1) WO2022081033A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3860603A1 (en) 2018-10-05 2021-08-11 Neurocrine Biosciences, Inc. Methods for the administration of comt inhibitors
JP2024500754A (ja) * 2020-12-17 2024-01-10 ビアル－ポルテラ エ コンパニア，ソシエダッド アノニマ 早期特発性パーキンソン病のための治療レジメン
GB202212082D0 (en) * 2022-08-18 2022-10-05 Bial Portela & Ca Sa Treatment regimens for parkinson's disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107708A9 (en) * 2011-02-11 2013-02-14 Bial - Portela & Ca, S.A. Administration regime for nitrocatechols
US20170165381A1 (en) * 2015-10-09 2017-06-15 Teva Pharmaceuticals International Gmbh Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease
US20170340593A1 (en) * 2014-11-28 2017-11-30 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
CN108349993A (zh) * 2015-08-27 2018-07-31 普雷克斯顿医疗股份公司 用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110002462A (ko) 2008-03-17 2011-01-07 바이알 - 포르텔라 앤드 씨에이 에스에이 5-[3-(2,5-디클로로-4,6-디메틸-1-옥시-피리딘-3-일)-[1,2,4]옥사디아졸-5-일]-3-나이트로벤젠-1,2-디올의 결정형
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
RU2550133C2 (ru) 2009-04-01 2015-05-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Фармацевтические составы, включающие производные нитрокатехола, и способы их получения
WO2013089573A1 (en) 2011-12-13 2013-06-20 BIAL - PORTELA & Cª., S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
JP2020023540A (ja) * 2019-10-11 2020-02-13 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012107708A9 (en) * 2011-02-11 2013-02-14 Bial - Portela & Ca, S.A. Administration regime for nitrocatechols
US20170340593A1 (en) * 2014-11-28 2017-11-30 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
JP2018500300A (ja) * 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
CN108349993A (zh) * 2015-08-27 2018-07-31 普雷克斯顿医疗股份公司 用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物
US20170165381A1 (en) * 2015-10-09 2017-06-15 Teva Pharmaceuticals International Gmbh Combination of Deuterated Levodopa With Carbidopa and Opicapone For The Treatment of Parkinson's Disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMA说明书: "ONGENTYS (opicapone) capsules", pages 1 - 2, Retrieved from the Internet <URL:ongentys.com/taking-ongentys/> *
HEINZ REICHMANN ET AL.: ""Effectiveness and satety of opicapone in Parkinson\'s disease patients with motor fluctuations: the OPTIPARK openlabel study"", TRANSLATIONAL NEURODEGENERATION, vol. 9, no. 9, 4 March 2020 (2020-03-04), pages 1 - 9 *
LMBRIANI PAOLA, ET AL.: ""Continuous dopaminergic stimulation in a patient treated with daytime Levodopa-carbidopa intestinal gel and overnight Rotigotine: a case report"", ACTA BIOMED, vol. 88, 23 August 2017 (2017-08-23), pages 190 - 195, XP055876213, DOI: 10.23750/abm.v88i2.5038 *

Also Published As

Publication number Publication date
GB202016425D0 (en) 2020-12-02
AU2021360114A9 (en) 2024-10-17
EP4228618A1 (en) 2023-08-23
JP2023546140A (ja) 2023-11-01
AU2021360114A1 (en) 2023-06-08
WO2022081033A1 (en) 2022-04-21
KR20230088753A (ko) 2023-06-20
US20230398105A1 (en) 2023-12-14

Similar Documents

Publication Publication Date Title
US20250275934A1 (en) Medicaments for slowing parkinson&#39;s disease
Fox et al. The movement disorder society evidence‐based medicine review update: Treatments for the motor symptoms of Parkinson's disease
CN116490171A (zh) 用于治疗帕金森病的阿片哌酮和左旋多巴
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
KR20240110935A (ko) 대사 장애를 치료하는 방법
US11439613B2 (en) Levodopa fractionated dose composition and use
Oertel et al. Early (uncomplicated) Parkinson’s disease
JP7485874B2 (ja) 神経変性障害の治療のための医薬組成物の連続的投与
US20260053782A1 (en) Treatment regimens for parkinson&#39;s disease
Musey et al. Medical therapies for motor symptoms in Parkinson’s Disease
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
CA3095341C (en) Levodopa fractionated dose composition and use
Truong et al. Parkinson's disease
CN116829145A (zh) 早期特发性帕金森病的治疗方案
CN121943902A (zh) T-型钙通道调节剂的制剂及其使用方法
Rizek et al. Management of Advanced Parkinson’s Disease
Waters Pharmacologic management of Parkinson disease: Treatment of levodopa-associated" wearing off"
JPWO2020189781A1 (ja) パーキンソン病治療剤
Katzenschlager of Parkinson’s Disease
Vasconcelos et al. European Commission approves ONGENTYS®(opicapone)–a novel treatment for Parkinsons disease patients with motor fluctuations
HK1119078A (en) Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination